Anti-VEGF-A pre-treatment led to a greater than 2-fold increase in distribution and a 3-fold increase in replication of CRAd-S-pk7 associated with significantly increased tumor doubling time compared to control treatments. This evidence concerns the gene VEGFA and neoplasm.